Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Neuropsychopharmacology. 2013 Sep;38(10):2003-10. doi: 10.1038/npp.2013.99. Epub 2013 Apr 23. Erratum in: Neuropsychopharmacology. 2014 Mar;39(4):1039.

2.

Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH.

Pharmacogenomics J. 2014 Jun;14(3):303-8. doi: 10.1038/tpj.2013.30. Epub 2013 Oct 15.

3.

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.

4.

Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.

Piralishvili G, Otiashvili D, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

J Subst Abuse Treat. 2015 Mar;50:32-7. doi: 10.1016/j.jsat.2014.10.003. Epub 2014 Oct 22.

PMID:
25456093
5.

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Mattick RP, Breen C, Kimber J, Davoli M.

Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4. Review.

PMID:
24500948
6.

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.

Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Doyle GA, Lohoff FW, Berrettini WH.

Drug Alcohol Depend. 2013 Jan 1;127(1-3):122-8. doi: 10.1016/j.drugalcdep.2012.06.023. Epub 2012 Jul 12.

7.

Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W.

Addiction. 2016 Apr;111(4):695-705. doi: 10.1111/add.13238. Epub 2016 Jan 13.

8.

Opioid agonist treatment for pharmaceutical opioid dependent people.

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N.

Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.

PMID:
27157143
9.

Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

J Clin Psychopharmacol. 1996 Feb;16(1):58-67.

PMID:
8834420
10.

Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.

Curcio F, Franco T, Topa M, Baldassarre C; Gruppo Responsabili UO Sert T..

Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):871-4.

PMID:
21845796
11.

Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

Drug Alcohol Depend. 2013 Dec 1;133(2):376-82. doi: 10.1016/j.drugalcdep.2013.06.024. Epub 2013 Jul 31.

12.

Opioid dependence: rationale for and efficacy of existing and new treatments.

Fiellin DA, Friedland GH, Gourevitch MN.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S173-7. Review.

PMID:
17109303
13.

Narrative review: buprenorphine for opioid-dependent patients in office practice.

Sullivan LE, Fiellin DA.

Ann Intern Med. 2008 May 6;148(9):662-70. Review.

14.

Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.

Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA.

J Addict Med. 2012 Dec;6(4):274-9. doi: 10.1097/ADM.0b013e31826d1df3.

15.

Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.

Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR.

Arch Gen Psychiatry. 1999 Sep;56(9):812-20.

PMID:
12884887
16.

Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.

Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS.

Addiction. 2016 May;111(5):874-82. doi: 10.1111/add.13259. Epub 2016 Jan 26.

PMID:
26639678
17.

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS.

N Engl J Med. 2006 Jul 27;355(4):365-74.

18.

[Heroin substitution treatments. Analysis of current solutions, trends, and perspectives].

Guffens JM.

Acta Clin Belg. 2006;61 Suppl 1:18-24. French.

PMID:
16700146
19.

Use and misuse of opioid replacement therapies: a Queensland study.

Smirnov A, Kemp R.

Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.

PMID:
22216993
20.

Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes.

Fonseca F, Gratacòs M, Escaramís G, De Cid R, Martín-Santos R, Fernández-Espejo E, Estivill X, Torrens M.

Mol Diagn Ther. 2010 Jun 1;14(3):171-8. doi: 10.2165/11537650-000000000-00000.

PMID:
20560679

Supplemental Content

Support Center